Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei September 3, 2024 12:15 CET Regulatory Read more
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ) September 3, 2024 12:00 CET Regulatory Read more
Invitation to the presentation of Calliditas´s interim report January – June 2024 August 5, 2024 07:00 CET Non Regulatory Read more
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy July 26, 2024 17:00 CET Non Regulatory Read more
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis July 26, 2024 08:00 CET Regulatory Read more
Launch of Phase 3 clinical trial with Nefecon in Japan July 4, 2024 08:30 CET Non Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) June 17, 2024 17:30 CET Regulatory Read more
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy May 30, 2024 20:00 CET Regulatory Read more
Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress May 28, 2024 14:00 CET Non Regulatory Read more
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation May 28, 2024 08:30 CET Regulatory Read more
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO’s Mode of Action May 16, 2024 16:30 CET Non Regulatory Read more
Invitation to the presentation of Calliditas´s interim report January – March 2024 May 16, 2024 08:30 CET Non Regulatory Read more
Calliditas Therapeutics to Present Data at ERA 2024 May 23 – 26 in Stockholm May 15, 2024 14:00 CET Non Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) May 15, 2024 12:00 CET Regulatory Read more
Calliditas’ Partner Everest Medicines Starts Commercial Launch of Nefecon in China May 14, 2024 13:00 CET Non Regulatory Read more
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib May 6, 2024 08:00 CET Regulatory Read more
Calliditas Announces Positive NefIgArd Open Label Extension Results April 24, 2024 08:30 CET Non Regulatory Read more
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024 April 18, 2024 13:00 CET Non Regulatory Read more
Calliditas Therapeutics to Attend Conferences in April April 9, 2024 13:00 CET Non Regulatory Read more
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 – 16 in Buenos Aires April 8, 2024 14:00 CET Non Regulatory Read more
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment April 8, 2024 09:00 CET Non Regulatory Read more
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO® March 6, 2024 08:15 CET Regulatory Read more
Calliditas Therapeutics to Attend Investor Conferences in March March 1, 2024 13:00 CET Non Regulatory Read more
Invitation to the presentation of Calliditas´ Year-end report January – December 2023 February 14, 2024 07:00 CET Non Regulatory Read more
Calliditas Therapeutics provides business update ahead of JP Morgan conference January 8, 2024 08:15 CET Regulatory Read more
Calliditas Therapeutics appoints Maria Törnsén as President North America January 7, 2024 17:00 CET Non Regulatory Read more
Calliditas to present at JP Morgan Healthcare Conference January 7, 2024 15:00 CET Non Regulatory Read more
